Gq/11-mediated signaling and hypertrophy in mice with cardiac-specific transgenic expression of regulator of G-protein signaling 2

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Park Windhol, Cindy ^a   Zhang, Peng ^a   Zhu, Ming ^a   Su, Jialin ^a   Chaves, Leonard ^a   Maldonado, Angel E ^a   King, Michelle E ^a   Rickey, Lisa ^a   Cullen, Darragh ^b   Mende, Ulrike ^a  

^a BROWN UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ENDOTHELIN 1; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; MESSENGER RNA; PHOSPHOLIPASE C BETA; RGS PROTEIN; RGS2 PROTEIN; RGS4 PROTEIN; RGS5 PROTEIN; UNCLASSIFIED DRUG;

ADULTHOOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HEART HEMODYNAMICS; HEART HYPERTROPHY; HEART LEFT ATRIUM; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HEART RIGHT ATRIUM; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; TRANSGENIC MOUSE; TRANSVERSE AORTA CONSTRICTION;

MUS; MUS MUSCULUS;

EID: 84863617015     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040048     Document Type: Article

References (56)

1. Vakili BA, Okin PM, Devereux RB, (2001) Prognostic implications of left ventricular hypertrophy. Am Heart J 141: 334-341.
2. Frey N, Katus HA, Olson EN, Hill JA, (2004) Hypertrophy of the heart: a new therapeutic target? Circulation 109: 1580-1589.
3. Akhter SA, Luttrell LM, Rockman HA, Iaccarino G, Lefkowitz RJ, et al. (1998) Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 280: 574-577.
4. Wettschureck N, Rutten H, Zywietz A, Gehring D, Wilkie TM, et al. (2001) Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Gαq/Gα11 in cardiomyocytes. Nat Med 7: 1236-1240.
5. Zhang P, U M, (2011) Regulators of G-protein Signaling in the heart and their potential as therapeutic targets. Circ Res 109: 320-333.
6. Tesmer JJ, Berman DM, Gilman AG, Sprang SR, (1997) Structure of RGS4 bound to AlF4-activated Giα1: stabilization of the transition state for GTP hydrolysis. Cell 89: 251-261.
7. Berman DM, Kozasa T, Gilman AG, (1996) The GTPase-activating protein RGS4 stabilizes the transition state for nucleotide hydrolysis. J Biol Chem 271: 27209-27212.
8. Hepler JR, Berman DM, Gilman AG, Kozasa T, (1997) RGS4 and GAIP are GTPase-activating proteins for Gqα and block activation of phospholipase C β by γ-thio-GTP-Gqα. Proc Natl Acad Sci U S A 94: 428-432.
9. Yan Y, Chi PP, Bourne HR, (1997) RGS4 inhibits Gq-mediated activation of mitogen-activated protein kinase and phosphoinositide synthesis. J Biol Chem 272: 11924-11927.
10. Sinnarajah S, Dessauer CW, Srikumar D, Chen J, Yuen J, et al. (2001) RGS2 regulates signal transduction in olfactory neurons by attenuating activation of adenylyl cyclase III. Nature 409: 1051-1055.
11. Hao J, Michalek C, Zhang W, Zhu M, Xu X, et al. (2006) Regulation of cardiomyocyte signaling by RGS proteins: Differential selectivity towards G proteins and susceptibility to regulation. J Mol Cell Cardiol 41: 51-61.
12. Rogers JH, Tsirka A, Kovacs A, Blumer KJ, Dorn GW, 2nd, et al (2001) RGS4 reduces contractile dysfunction and hypertrophic gene induction in Gαq overexpressing mice. J Mol Cell Cardiol 33: 209-218.
13. Li H, He C, Feng J, Zhang Y, Tang Q, et al. (2010) Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload. Proc Natl Acad Sci U S A 107: 13818-13823.
14. Zhang W, Anger T, Su J, Hao J, Xu X, et al. (2006) Selective loss of fine tuning of Gq/11 signaling by RGS2 protein exacerbates cardiomyocyte hypertrophy. J Biol Chem 281: 5811-5820.
15. Takimoto E, Koitabashi N, Hsu S, Ketner EA, Zhang M, et al. (2009) Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest 119: 408-420.
16. Zou MX, Roy AA, Zhao Q, Kirshenbaum LA, Karmazyn M, et al. (2006) RGS2 is upregulated by and attenuates the hypertrophic effect of α1-adrenergic activation in cultured ventricular myocytes. Cell Signal 18: 1655-1663.
17. Bowman JC, Steinberg SF, Jiang T, Geenen DL, Fishman GI, et al. (1997) Expression of protein kinase C β in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest 100: 2189-2195.
18. Syed F, Odley A, Hahn HS, Brunskill EW, Lynch RA, et al. (2004) Physiological growth synergizes with pathological genes in experimental cardiomyopathy. Circ Res 95: 1200-1206.
19. Sanbe A, Gulick J, Hanks MC, Liang Q, Osinska H, et al. (2003) Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res 92: 609-616.
20. Anger T, Zhang W, Mende U, (2004) Differential contribution of GTPase activation and effector antagonism to the inhibitory effect of RGS proteins on Gq-mediated signaling. J Biol Chem 276: 3906-3915.
21. Posokhova E, Wydeven N, Allen KL, Wickman K, Martemyanov KA, (2010) RGS6/Gβ5 complex accelerates IKACh gating kinetics in atrial myocytes and modulates parasympathetic regulation of heart rate. Circ Res 107: 1350-1354.
22. Yang J, Huang J, Maity B, Gao Z, Lorca RA, et al. (2010) RGS6, a modulator of parasympathetic activation in heart. Circ Res 107: 1345-1349.
23. Benjamin EJ, Levy D, (1999) Why is left ventricular hypertrophy so predictive of morbidity and mortality? Am J Med Sci 317: 168-175.
24. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP, (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322: 1561-1566.
25. Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, et al. (2002) Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105: 85-92.
26. Hill JA, Karimi M, Kutschke W, Davisson RL, Zimmerman K, et al. (2000) Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation 101: 2863-2869.
27. Hill JA, Rothermel B, Yoo KD, Cabuay B, Demetroulis E, et al. (2002) Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic function. J Biol Chem 277: 10251-10255.
28. McKinsey TA, Olson EN, (2005) Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J Clin Invest 115: 538-546.
29. Koitabashi N, Kass DA, (2012) Reverse remodeling in heart failure- mechanisms and therapeutic opportunities. Nat Rev Cardiol 9: 147-157.
30. Hardt SE, Sadoshima J, (2004) Negative regulators of cardiac hypertrophy. Cardiovasc Res 63: 500-509.
31. Leenders JJ, Pinto YM, Creemers EE, (2011) Tapping the brake on cardiac growth- endogenous repressors of hypertrophic signaling. J Mol Cell Cardiol 51: 156-167.
32. McCloskey DT, Turnbull L, Swigart PM, Zambon AC, Turcato S, et al. (2005) Cardiac transgenesis with the tetracycline transactivator changes myocardial function and gene expression. Physiol Genomics 22: 118-126.
33. Errami M, Galindo CL, Tassa AT, Dimaio JM, Hill JA, et al. (2008) Doxycycline attenuates isoproterenol- and transverse aortic banding-induced cardiac hypertrophy in mice. J Pharmacol Exp Ther 324: 1196-1203.
34. Vinet L, Rouet-Benzineb P, Marniquet X, Pellegrin N, Mangin L, et al. (2008) Chronic doxycycline exposure accelerates left ventricular hypertrophy and progression to heart failure in mice after thoracic aorta constriction. Am J Physiol Heart Circ Physiol 295: H352-360.
35. Sheridan DJ, Autelitano DJ, Wang B, Percy E, Woodcock EA, et al. (2000) Beta2-adrenergic receptor overexpression driven by alpha-MHC promoter is downregulated in hypertrophied and failing myocardium. Cardiovasc Res 47: 133-141.
36. Genomics of Cardiovascular Development, Adaptation, and Remodeling. NHLBI Program for Genomics Applications, Harvard Medical School. URL http://www.cardiogenomics.org.
37. Oka T, Xu J, Kaiser RA, Melendez J, Hambleton M, et al. (2007) Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circ Res 101: 313-321.
38. Salim S, Sinnarajah S, Kehrl JH, Dessauer CW, (2003) Identification of RGS2 and type V adenylyl cyclase interaction sites. J Biol Chem 278: 15842-15849.
39. Osei-Owusu P, Sabharwal R, Kaltenbronn KM, Rhee MH, Chapleau MW, et al. (2012) Regulator of G Protein Signaling 2 deficiency causes endothelial dysfunction and impaired endothelium-derived hyperpolarizing factor-mediated relaxation by dysregulating Gi/o signaling. J Biol Chem 287: 12541-12549.
40. Chakir K, Zhu W, Tsang S, Woo AY, Yang D, et al. (2011) RGS2 is a primary terminator of β2-adrenergic receptor-mediated Gi signaling. J Mol Cell Cardiol 50: 1000-1007.
41. Nakayama H, Bodi I, Maillet M, DeSantiago J, Domeier TL, et al. (2010) The IP3 receptor regulates cardiac hypertrophy in response to select stimuli. Circ Res 107: 659-666.
42. Cunningham ML, Waldo GL, Hollinger S, Hepler JR, Harden TK, (2001) Protein kinase C phosphorylates RGS2 and modulates its capacity for negative regulation of Gα11 signaling. J Biol Chem 276: 5438-5444.
43. Tang M, Wang G, Lu P, Karas RH, Aronovitz M, et al. (2003) Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med 9: 1506-1512.
44. Jones TL, (2004) Role of palmitoylation in RGS protein function. Methods Enzymol 389: 33-55.
45. Ni J, Qu L, Yang H, Wang M, Huang Y, (2006) Palmitoylation and its effect on the GTPase-activating activity and conformation of RGS2. Int J Biochem Cell Biol 38: 2209-2218.
46. Bootman MD, Higazi DR, Coombes S, Roderick HL, (2006) Calcium signalling during excitation-contraction coupling in mammalian atrial myocytes. J Cell Sci 119: 3915-3925.
47. Zhao XS, Gallardo TD, Lin L, Schageman JJ, Shohet RV, (2002) Transcriptional mapping and genomic analysis of the cardiac atria and ventricles. Physiol Genomics 12: 53-60.
48. Nattel S, (2009) G-protein signaling and arrhythmogenic atrial remodeling: relevance to novel therapeutic targets in atrial fibrillation. Heart Rhythm 6: 85-86.
49. Hirose M, Takeishi Y, Niizeki T, Shimojo H, Nakada T, et al. (2009) Diacylglycerol kinase ζ inhibits Gαq-induced atrial remodeling in transgenic mice. Heart Rhythm 6: 78-84.
50. Tuomi JM, Chidiac P, Jones DL, (2010) Evidence for enhanced M3 muscarinic receptor function and sensitivity to atrial arrhythmia in the RGS2-deficient mouse. Am J Physiol Heart Circ Physiol 298: H554-561.
51. Mayyas F, Niebauer M, Zurick A, Barnard J, Gillinov AM, et al. (2010) Association of left atrial endothelin-1 with atrial rhythm, size, and fibrosis in patients with structural heart disease. Circ Arrhythm Electrophysiol 3: 369-379.
52. Woodcock EA, Grubb DR, Filtz TM, Marasco S, Luo J, et al. (2009) Selective activation of the "b" splice variant of phospholipase Cβ1 in chronically dilated human and mouse atria. J Mol Cell Cardiol 47: 676-683.
53. Tarnavski O, McMullen JR, Schinke M, Nie Q, Kong S, et al. (2004) Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies. Physiol Genomics 16: 349-360.
54. Pacher P, Nagayama T, Mukhopadhyay P, Batkai S, Kass DA, (2008) Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc 3: 1422-1434.
55. Cingolani OH, Kass DA, (2011) Pressure-volume relation analysis of mouse ventricular function. Am J Physiol Heart Circ Physiol 301: H2198-2206.
56. Mende U, Kagen A, Cohen A, Aramburu J, Schoen FJ, et al. (1998) Transient cardiac expression of constitutively active Gαq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci U S A 95: 13893-13898.